Cobimetinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cobimetinib: From Metastatic Melanoma to Amyotrophic Lateral Sclerosis
One-Sentence Summary
Cobimetinib is an oral MEK inhibitor originally used to treat metastatic melanoma. The TxGNN model predicts it may be effective for amyotrophic lateral sclerosis (ALS), but this is a computational prediction only, with no clinical trials and no publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Metastatic melanoma (from the knowledge graph; the Singapore licence has no indication text on file) |
| Predicted New Indication | Amyotrophic lateral sclerosis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge of the drug class, cobimetinib inhibits MEK1/2, key kinases in the MAPK/ERK signalling pathway. Its efficacy in metastatic melanoma is tied to blocking this pathway in tumour cells.
Dysregulated MAPK/ERK signalling and neuroinflammation have been proposed as contributors to ALS, which gives a plausible but unvalidated rationale. This link rests on general knowledge, not on data supplied for this report. The high TxGNN score is a computational prediction and not proof of efficacy.
A further concern is that cobimetinib has limited brain penetrance, which is a drawback for a disease of the central nervous system.
Other top-ranked predictions are mostly motor neuron diseases or ALS variants (such as ALS type 22, Mills syndrome, and lower motor neuron syndrome). These probably reflect the same ALS-related signal in the knowledge graph rather than independent support. The remaining predictions (for example polymicrogyria, axial spondylometaphyseal dysplasia, and a lethal arthrogryposis syndrome) have no identified mechanistic link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15219P | COTELLIC FILM-COATED TABLET 20 MG | Film-coated tablet (oral) | Not available |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (MEK inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Drug Interactions: 266 potential interactions were identified. Examples of those rated Major:
- Aprepitant
- Dexamethasone
- Clarithromycin
- Cobicistat
- Samarium (153Sm) lexidronam
Examples rated Moderate include cimetidine, clotrimazole, miconazole, naltrexone, ticagrelor, quinine, and ivacaftor.
Many of these interacting drugs affect drug-metabolising enzymes, so concomitant medicines would need careful review. For other safety information, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based only on a computational score, with no clinical trials or literature. The mechanistic rationale is speculative, brain penetrance is limited, and the many drug interactions add risk. Most of the other top predictions appear to duplicate the ALS signal or lack any mechanistic link. ALS is the only one that could be treated as a research question.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data
- Preclinical evidence of MEK inhibition benefit in ALS models, including CNS exposure data
- A review of published literature and trial registries for MEK inhibitors in motor neuron disease
- A risk-benefit assessment for a chronic neurological indication, given the toxicity profile and drug interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.